Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Recruitment completed for Betaseron BEYOND study
August 15th, 2005
Berlex, Inc., and its parent company Schering AG, Germany (SCH; SHR), announced that more than 2100 patients with relapsing-remitting multiple sclerosis (RRMS) have been enrolled into the BEYOND (Betaseron Efficacy Yielding Outcomes of a New Dose) study, thereby reaching the study's enrollment goal. BEYOND is the largest-ever, randomized, blinded, clinical MS study and is being conducted in nearly 200 centers in 26 countries. With more than 16 years of clinical trial and real world experience, Betaseron 250 mcg is a proven, effective and well-tolerated therapy for relapsing forms of multiple sclerosis. The BEYOND study is evaluating if patients with...
Source: Pharma Business Week (2005-08-15)
|
